Galderma Q3 Sales Jump 26.6% to $1.63 Billion; Raises FY26 Sales Guidance, Shares Up 4%

Galderma Group AG (GALD.SW, GALDY) reported third-quarter sales of $1.63 billion, up 26.6% from $1.29 billion a year earlier, and raised its fiscal 2026 net sales growth outlook to 22.5%-23.5% at constant currency from a prior 19%-21% range. Shares rose 4.07% to 181.35 Swiss francs in Switzerland. Constant-currency sales grew 26.0%. U.S. sales climbed 39.4% to $755 million, while international sales rose 17.2% to $876 million. By category, Injectable Aesthetics sales grew 16.7% to $736 million, Dermatological Skincare rose 15.4%, and Therapeutic Dermatology jumped 58.5%. The company reaffirmed its expectation of an annual Core EBITDA margin of approximately 26% at constant currency.